MicroPort CardioFlow-TAVR (02160): The VitaFlow series of transcatheter aortic valve and delivery systems has entered 35 countries and regions worldwide, with a cumulative implantation of nearly 1300 cases.

Minimally Invasive Heart-In-B(02160) announced that as of the date of this announcement, the group's VitaFow series of transcatheter aortic valve and delivery systems have entered 35 countries and regions worldwide, with a cumulative implantation of nearly 1,300 cases. Among them, the predicted implantation volume for 2025 is expected to exceed 850 cases, representing a growth of nearly 350% compared to 2024. In the second half of 2025, benefiting from the continued commercial expansion of VitaFow Liberty in European countries after obtaining CE certification, as well as the sustained increase in market share in emerging market countries in Asia and Latin America, the implantation volume is expected to grow by over 170% compared to the first half of the year. The Board of Directors believes that through the recent completion of the acquisition of Minimally Invasive Arrhythmia Management, the group will further strengthen localization channel resources and clinical support systems in mature markets such as Europe, significantly enhancing the new market access efficiency and market penetration depth of TAVI products. In the future, the group will continue to unlock the synergy potential of business integration, advance the research and clinical progress of next-generation TAVI products, further improve structural heart disease solutions, and comprehensively enhance the group's overall competitive strength in the global valve therapy field.